Alberta / covid 19

Immunocompromised Albertans eligible for fourth dose

News Release

Immunocompromised Albertans eligible for fourth dose

More than 80,000 Albertans will soon be able to receive fourth doses of COVID-19 vaccine to bolster immunity.

In line with recommendations from the National Advisory Committee on Immunization (NACI) and the Alberta Advisory Committee on Immunization (AACI), individuals aged 18 and older who have specific immunocompromising conditions can receive a booster five months after receiving their third dose.

Beginning Jan. 20, eligible individuals can book appointments for fourth doses online with AHS and participating pharmacies by using the Alberta vaccine booking system or by calling 811.

“We remain committed to protecting Albertans from the Omicron variant, and vaccinations continue to be our best tool in preventing severe outcomes. We continue to rely on the latest research to guide our decision-making, and with evidence showing immunocompromised individuals benefit from a fourth dose, we are pleased to provide them.”Jason Kenney, Premier

“I know that the approximately 80,000 Albertans who live with immunocompromising conditions will be relieved to receive these additional doses. At the same time, the best way for all of us to protect ourselves and one another is to continue getting whatever dose we are eligible for. I encourage all Albertans to continue to sign up for their booster doses as soon as they can.”Jason Copping, Minister of Health

“Individuals with certain immunocompromising conditions can benefit from a fourth COVID-19 vaccine dose. With the rapid spread of the Omicron variant, we want to provide these Albertans with additional protection against the virus.”Dr. Deena Hinshaw, chief medical officer of health

Qualifying conditions

Immunocompromising conditions that qualify adults aged 18 and older for a fourth dose at least five months after a third dose include:

  • Transplant recipients, including solid organ transplants and hematopoietic stem cell transplants.
  • Individuals with malignant hematologic disorders and non-hematologic malignant solid tumors prior to receiving or receiving active treatment (chemotherapy, targeted therapies, immunotherapy or having received previous COVID-19 vaccines while on active treatment), excluding individuals receiving solely hormonal therapy, radiation therapy or a surgical intervention.
  • Individuals being treated with an anti-CD20 monoclonal antibody such as Rituximab.
  • Individuals with chronic kidney disease on dialysis.
  • Recipients of chimeric antigen receptor (CAR)-T-cell therapy.
  • Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
  • Individuals with Stage 3 or advanced HIV infection and those with acquired COVID-19 immunization.
  • Individuals undergoing immunosuppressive therapies (e.g., anti-B cell therapies, high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumornecrosis factor (TNF) inhibitors and other biologic agents).
  • Individuals on certain medications for autoimmune diseases, including rituximab, ocrelizumab and ofatumumab.

Youth ages 12 to 17 with the preceding conditions continue to be eligible for third doses. Fourth doses have not yet been approved for this age group.

Third doses have not been approved for youth under the age of 18.

Appointments for additional doses

Eligible Albertans can book appointments online for AHS or participating pharmacies by using the one-stop booking system at Albertans can also book an appointment by calling 811 or participating pharmacies.

For schedule and locations, visit

Related information


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.